Treating MERS-CoV during an outbreak.
Identifieur interne : 001827 ( PubMed/Curation ); précédent : 001826; suivant : 001828Treating MERS-CoV during an outbreak.
Auteurs : Christopher M. Coleman [États-Unis] ; Matthew B. Frieman [États-Unis]Source :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Antiviraux, Interféron alpha, Protéines recombinantes, Ribavirine.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Femelle, Humains, Mâle.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Recombinant Proteins, Ribavirin.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- drug therapy : Coronavirus Infections.
- Female, Humans, Interferon alpha-2, Male.
DOI: 10.1016/S1473-3099(14)70939-9
PubMed: 25278219
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001827
Links to Exploration step
pubmed:25278219Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treating MERS-CoV during an outbreak.</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25278219</idno><idno type="pmid">25278219</idno><idno type="doi">10.1016/S1473-3099(14)70939-9</idno><idno type="wicri:Area/PubMed/Corpus">001827</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001827</idno><idno type="wicri:Area/PubMed/Curation">001827</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001827</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treating MERS-CoV during an outbreak.</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M" last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201</wicri:regionArea></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B" last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Female</term><term>Humans</term><term>Interferon alpha-2</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Femelle</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interféron alpha (usage thérapeutique)</term><term>Mâle</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Ribavirine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Interferon alpha-2</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Femelle</term><term>Humains</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">25278219</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Treating MERS-CoV during an outbreak.</ArticleTitle><Pagination><MedlinePgn>1030-1031</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(14)70939-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(14)70939-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frieman</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI095569</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet Infect Dis. 2014 Nov;14(11):1090-5</RefSource><PMID Version="1">25278221</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25278219</ArticleId><ArticleId IdType="pii">S1473-3099(14)70939-9</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(14)70939-9</ArticleId><ArticleId IdType="pmc">PMC7128167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clinicoecon Outcomes Res. 2014 Apr 25;6:217-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24812523</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Gastroenterology. 2010 Jan;138(1):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19852964</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2008 Apr;78(1):162-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18093668</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2008 Apr;78(1):103-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18241935</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001827 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001827 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25278219
|texte= Treating MERS-CoV during an outbreak.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25278219" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |